Posted by Michael Wonder on 14 Oct 2016
TGA publishes AusPAR for Zurampic
14 October 2016 - The TGA has published an AusPAR for AstraZeneca's Zurampic.
The TGA approved Zurampic on 16 May 2016 for use in combination with a xanthine oxidase inhibitor for the treatment of hyperuricaemia associated with gout in patients who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor alone.
